Integrating ADCs Into the Treatment Paradigm in in EGFR-Mutant NSCLC

Heather Wakelee, MD, and Helena Yu, MD, explore the growing role of antibody-drug conjugates (ADCs) in EGFR-mutant non–small cell lung cancer, particularly in the post-osimertinib setting. They discuss whether ADCs are beginning to replace chemotherapy in certain scenarios and their potential as resistance-agnostic treatment options. The conversation also addresses whether these agents should move earlier in the treatment paradigm and how prior chemotherapy exposure may influence their efficacy.